# Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study

> **NCT04880746** · PHASE3 · UNKNOWN · sponsor: **Ruijin Hospital** · enrollment: 266 (estimated)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** BEAC
- **DRUG:** Cladribine combined with BEAC

## Key facts

- **NCT ID:** NCT04880746
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-17
- **Primary completion:** 2024-10-17
- **Final completion:** 2025-10-17
- **Target enrollment:** 266 (ESTIMATED)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04880746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04880746, "Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04880746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*